{"id":1941,"date":"2015-12-04T02:08:28","date_gmt":"2015-12-04T02:08:28","guid":{"rendered":"https:\/\/colox.ch\/novigenix\/"},"modified":"2019-08-29T11:48:21","modified_gmt":"2019-08-29T09:48:21","slug":"novigenix","status":"publish","type":"page","link":"https:\/\/colox.ch\/de\/novigenix\/","title":{"rendered":"Novigenix"},"content":{"rendered":"

<\/div>
<\/div>
<\/div>
<\/div>

\u00dcber uns<\/span><\/h1>\n<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/span><\/div>
<\/div>
<\/div>
<\/div>

Innovation in liquid biopsy to eradicate cancer<\/h1>\n<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div>
<\/span><\/div>
<\/div><\/div><\/div>

Novigenix ist ein innovatives Schweizer Molekulardiagnostik-Unternehmen mit Schwerpunkt Bluttests der neuesten Generation f\u00fcr die Krebs-Fr\u00fcherkennung.<\/p>\n

Die Technologie von Novigenix basiert auf einer neuen Generation genetischer Expressionsprofile zirkulierender Blutzellen und aus Tumoren stammender Proteinmarker in Verbindung mit modernsten mathematischen Analysemodellen.<\/p>\n

Unsere pr\u00e4diktiven molekularen Signaturen bieten neue und pr\u00e4zise L\u00f6sungen f\u00fcr die Krebsfr\u00fcherkennung.<\/p>\n

Unser wichtigstes Produkt, Colox\u00ae, ist ein bew\u00e4hrter molekularer Bluttest mit dem Ziel, die Mortalit\u00e4t von Kolorektalkrebs durch fr\u00fchzeitige Erkennung und anschliessende Kolonoskopie signifikant zu senken.<\/p>\n<\/div>

<\/div>
<\/div>
<\/div>
Learn more about Novigenix<\/span><\/a><\/div>
<\/div><\/div><\/div><\/div><\/div>
<\/div>
<\/div>
<\/div>
<\/div>

Wissenschaftliche Berater<\/span><\/h1>\n<\/div>
<\/div>
<\/div>
<\/div>
<\/div><\/div><\/div><\/div><\/div>

Dr. Marianne Murphy<\/strong><\/h3>\n

Immunologist with international recognition in the fields of T cell and cytokine biology, and with 25 years of industry experience in various leading positions at NatiMab Therapeutics, RiboVax Biotechnologies, and Celltech R&D.<\/p>\n

<\/h3>\n

Dr. Reinhard Ebner<\/strong><\/h3>\n

Senior research manager and investigator specialized in solving complex questions in molecular and cell biology, particularly as they relate to disease mechanism and drug discovery. More than 30 years of experience in US academia and industrie (Stanford, Genentech, NIH, Cytotest).<\/p>\n

<\/h3>\n

Prof. Stephan Morgenthaler<\/strong><\/h3>\n

Full Professor at Ecole Polytechnique F\u00e9d\u00e9rale de Lausanne (EPFL), Chair of Applied Statistics, Lausanne, Switzerland<\/p>\n

<\/h3>\n

Dr. Antoine de Weck<\/strong><\/h3>\n

Investigator at Novartis Institute for Biomedical Research and specialist in Computational Biology, Basel, Switzerland<\/p>\n<\/div>

<\/div><\/div><\/div>

Prof. Christoph Beglinger, MD<\/strong><\/h3>\n

Specialist in Gastroenterology, formerly Head of the Department of Biomedicine at the University Hospital of Basel, currently Head of Clinical Research at St. Claraspital in Basel, Switzerland<\/p>\n

<\/h3>\n

Prof. Gian Dorta, MD<\/strong><\/h3>\n

Specialist in Gastroenterology, Department of Internal Medicine, Section Gastroenterology and Hepatology, Academic Medical Center, Lausanne (CHUV), Switzerland<\/p>\n

<\/h3>\n

Dr. Cristina Nichita, MD<\/strong><\/h3>\n

Specialist in Gastroenterology, Centre M\u00e9dical d\u2019Epalinge, VIDY MED Group, Epalinges, Switzerland<\/p>\n

<\/h3>\n

Prof. Peter Bauerfeind, MD<\/strong><\/h3>\n

Specialist in Gastroenterology, Clinic for Gastroenterology and Hepatology, University Hospital, Zurich (USZ), Switzerland<\/p>\n

<\/h3>\n

Dr. Philippe Maerten, MD PhD<\/strong><\/h3>\n

Specialist in Gastroenterology, Hirslanden Clinic Cecil, Lausanne, Switzerland<\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":1951,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-1941","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nNovigenix - Colox<\/title>\n<meta name=\"description\" content=\"Als Startup-Unternehmen im Bereich Biotechnologie sehen wir uns als Change Agent mit der Aufgabe, einen tief greifenden Wandel herbeizuf\u00fchren.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/colox.ch\/de\/novigenix\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novigenix\" \/>\n<meta property=\"og:description\" content=\"Als Startup-Unternehmen im Bereich Biotechnologie sehen wir uns als Change Agent mit der Aufgabe, einen tief greifenden Wandel herbeizuf\u00fchren.\u00a0Darmkrebs ist in der Schweiz j\u00e4hrlich f\u00fcr 1.600\u00a0Todesf\u00e4lle verantwortlich. Obwohl Fr\u00fcherkennung die \u00dcberlebenschancen auf 90\u00a0% steigert, lassen sich nur 30\u00a0% der Bev\u00f6lkerung testen. Diese Realit\u00e4t ist untragbar.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/colox.ch\/de\/novigenix\/\" \/>\n<meta property=\"og:site_name\" content=\"Colox\" \/>\n<meta property=\"article:modified_time\" content=\"2019-08-29T09:48:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Novigenix\" \/>\n<meta name=\"twitter:description\" content=\"Als Startup-Unternehmen im Bereich Biotechnologie sehen wir uns als Change Agent mit der Aufgabe, einen tief greifenden Wandel herbeizuf\u00fchren.\u00a0Darmkrebs ist in der Schweiz j\u00e4hrlich f\u00fcr 1.600\u00a0Todesf\u00e4lle verantwortlich. Obwohl Fr\u00fcherkennung die \u00dcberlebenschancen auf 90\u00a0% steigert, lassen sich nur 30\u00a0% der Bev\u00f6lkerung testen. Diese Realit\u00e4t ist untragbar.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"9\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix\/\",\"url\":\"https:\/\/colox.ch\/de\/novigenix\/\",\"name\":\"Novigenix - Colox\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg\",\"datePublished\":\"2015-12-04T02:08:28+00:00\",\"dateModified\":\"2019-08-29T09:48:21+00:00\",\"description\":\"Als Startup-Unternehmen im Bereich Biotechnologie sehen wir uns als Change Agent mit der Aufgabe, einen tief greifenden Wandel herbeizuf\u00fchren.\",\"breadcrumb\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/colox.ch\/de\/novigenix\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix\/#primaryimage\",\"url\":\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg\",\"contentUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg\",\"width\":1200,\"height\":630,\"caption\":\"novigenix\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/colox.ch\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novigenix\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/colox.ch\/de\/#website\",\"url\":\"https:\/\/colox.ch\/de\/\",\"name\":\"Colox\",\"description\":\"The new generation blood test\",\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/colox.ch\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/colox.ch\/de\/#organization\",\"name\":\"Novigenix SA\",\"url\":\"https:\/\/colox.ch\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"contentUrl\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"width\":700,\"height\":297,\"caption\":\"Novigenix SA\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novigenix - Colox","description":"Als Startup-Unternehmen im Bereich Biotechnologie sehen wir uns als Change Agent mit der Aufgabe, einen tief greifenden Wandel herbeizuf\u00fchren.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/colox.ch\/de\/novigenix\/","og_locale":"de_DE","og_type":"article","og_title":"Novigenix","og_description":"Als Startup-Unternehmen im Bereich Biotechnologie sehen wir uns als Change Agent mit der Aufgabe, einen tief greifenden Wandel herbeizuf\u00fchren.\u00a0Darmkrebs ist in der Schweiz j\u00e4hrlich f\u00fcr 1.600\u00a0Todesf\u00e4lle verantwortlich. Obwohl Fr\u00fcherkennung die \u00dcberlebenschancen auf 90\u00a0% steigert, lassen sich nur 30\u00a0% der Bev\u00f6lkerung testen. Diese Realit\u00e4t ist untragbar.","og_url":"https:\/\/colox.ch\/de\/novigenix\/","og_site_name":"Colox","article_modified_time":"2019-08-29T09:48:21+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_title":"Novigenix","twitter_description":"Als Startup-Unternehmen im Bereich Biotechnologie sehen wir uns als Change Agent mit der Aufgabe, einen tief greifenden Wandel herbeizuf\u00fchren.\u00a0Darmkrebs ist in der Schweiz j\u00e4hrlich f\u00fcr 1.600\u00a0Todesf\u00e4lle verantwortlich. Obwohl Fr\u00fcherkennung die \u00dcberlebenschancen auf 90\u00a0% steigert, lassen sich nur 30\u00a0% der Bev\u00f6lkerung testen. Diese Realit\u00e4t ist untragbar.","twitter_image":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"9\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/colox.ch\/de\/novigenix\/","url":"https:\/\/colox.ch\/de\/novigenix\/","name":"Novigenix - Colox","isPartOf":{"@id":"https:\/\/colox.ch\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/colox.ch\/de\/novigenix\/#primaryimage"},"image":{"@id":"https:\/\/colox.ch\/de\/novigenix\/#primaryimage"},"thumbnailUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg","datePublished":"2015-12-04T02:08:28+00:00","dateModified":"2019-08-29T09:48:21+00:00","description":"Als Startup-Unternehmen im Bereich Biotechnologie sehen wir uns als Change Agent mit der Aufgabe, einen tief greifenden Wandel herbeizuf\u00fchren.","breadcrumb":{"@id":"https:\/\/colox.ch\/de\/novigenix\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/colox.ch\/de\/novigenix\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/colox.ch\/de\/novigenix\/#primaryimage","url":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg","contentUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2015\/12\/Image-sharing-Facebook-home-site-novigenix-DE-1200px.jpg","width":1200,"height":630,"caption":"novigenix"},{"@type":"BreadcrumbList","@id":"https:\/\/colox.ch\/de\/novigenix\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/colox.ch\/"},{"@type":"ListItem","position":2,"name":"Novigenix"}]},{"@type":"WebSite","@id":"https:\/\/colox.ch\/de\/#website","url":"https:\/\/colox.ch\/de\/","name":"Colox","description":"The new generation blood test","publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/colox.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/colox.ch\/de\/#organization","name":"Novigenix SA","url":"https:\/\/colox.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/","url":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","contentUrl":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","width":700,"height":297,"caption":"Novigenix SA"},"image":{"@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/pages\/1941"}],"collection":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/comments?post=1941"}],"version-history":[{"count":0,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/pages\/1941\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/media\/1951"}],"wp:attachment":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/media?parent=1941"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}